Editas Medicine (EDIT) Reports Q4 Loss of $1.00/sh

Editas Medicine (NASDAQ: EDIT) reported Q4 EPS of ($1.00), versus ($0.74) reported last year. Revenue for the quarter came in at $11.4 million, versus $12.3 million reported last year.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Sun Communities names Ileana McAlary as general counsel and EVP
• Pfizer lung cancer drug misses survival goal in Phase 3 trial